We serve Chemical Name:VO-Ohpic trihydrate CAS:476310-60-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:VO-Ohpic trihydrate
CAS.NO:476310-60-8
Synonyms:VO-Ohpic (trihydrate)
Molecular Formula:C12H16N2O11V
Molecular Weight:415.20
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like VO-Ohpic (trihydrate) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,VO-Ohpic (trihydrate) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,VO-Ohpic (trihydrate) Use and application,VO-Ohpic (trihydrate) technical grade,usp/ep/jp grade.
Related News: Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology. VO-Ohpic trihydrate manufacturer Adding Darzalex to Bristol Myers Squibb’s Revlimid and steroid dexamethasone (Rd) could slash the risk of death by 32% in newly diagnosed multiple myeloma patients ineligible to receive stem cell transplants, J&J reported at the European Hematology Association’s virtual congress. VO-Ohpic trihydrate supplier Any US citizen who has been in China’s Hubei province — epicenter of the outbreak — in the last 14 days will be allowed back into the country. VO-Ohpic trihydrate vendor Any US citizen who has been in China’s Hubei province — epicenter of the outbreak — in the last 14 days will be allowed back into the country. VO-Ohpic trihydrate factory Adding Darzalex to Bristol Myers Squibb’s Revlimid and steroid dexamethasone (Rd) could slash the risk of death by 32% in newly diagnosed multiple myeloma patients ineligible to receive stem cell transplants, J&J reported at the European Hematology Association’s virtual congress.
